We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Ultrasensitive Sensor Detects Down Syndrome in Womb

By HospiMedica International staff writers
Posted on 28 Feb 2019
A new biosensor could someday be used to detect fetal Down syndrome DNA in pregnant women's blood, according to a new study.

Developed by researchers at Peking University (Beijing, China), the National Research Institute for Family Planning of China (NHC; Beijing) and the Chinese Academy of Sciences (Shenyang, China), the highly sensitive DNA biosensors are based on a field-effect transistor (FET) fabricated using chemical vapor deposition grown monolayer molybdenum disulfide (MoS2) films. More...
The MoS2 is functionalized with gold nanoparticles of an optimized size and ideal density, allowing the DNA biosensor to probe for specific target immobilized on the nanoparticles.

Study results revealed that the fabricated FET biosensors were able to reliably detect target DNA fragments (chromosome 21 or 13) with a detection limit below 100 aM, a high response rate of up to 240%, and a high specificity, which satisfy the requirement for the screening of Down syndrome. In addition, a real-time in-vitro test was conducted to show that the biosensor clearly responds to the target DNA at concentrations as low as one fM. The study was published on February 13, 2019, in Nano Letters.

“Our approach shows the potential for detecting the over-expression of chromosome 21 in the peripheral blood of pregnant women,” concluded lead author Jingxia Liu, PhD, of Peking University, and colleagues. “Eventually, the test could be used to compare levels of chromosome 21 DNA in blood with that of another chromosome, such as 13, to determine if there are extra copies, suggesting a fetus has Down syndrome.”

Down syndrome, which is characterized by variable degrees of intellectual and developmental problems, is caused by the presence of an extra copy of chromosome 21. To screen for the condition, pregnant women can have ultrasound scans or indirect blood biomarker tests, but misdiagnosis rates are high. Amniocentesis can provides a definitive diagnosis, but the procedure poses risks to both the pregnant woman and the fetus. And while the emerging method of whole-genome sequencing is highly accurate, it is a slow and expensive process.

Related Links:
Peking University
National Research Institute for Family Planning of China
Chinese Academy of Sciences


Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Vessel Sealing Instrument
ERGOseal
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image:The NCIBT team with the cath lab members celebrating the completion of the study. (Image Credit: UC Davis)

Dual-Imaging Catheter Completes Initial Human Evaluation of Coronary Plaque

Atherosclerosis involves plaque buildup in arterial walls that can narrow blood vessels and increase the risk of heart attack, stroke, and other serious cardiovascular conditions. In coronary arteries,... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.